SynthesisBritish journal of clinical pharmacology2026
Systematic review and scoring-based selection of pharmacokinetic models for precision dosing of vancomycin in neonates and children.
Synthesis in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Systematic review and scoring-based selection of pharmacokinetic models for precision dosing of vancomycin in neonates and children.British journal of clinical pharmacology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Vancomycin is frequently used to treat gram-positive infections in neonates and children. The optimal marker for efficacy and toxicity is the 24-h area under the concentration-time curve/minimal inhibitory concentration, which can be estimated using population pharmacokinetic (popPK) models. These models can be integrated into model-informed precision dosing (MIPD) tools to personalize therapy. This study aimed to systematically review neonatal and paediatric vancomycin popPK models and develop a model selection tool for MIPD. A systematic literature search (December 2025; PubMed, EMBASE, WoS, Scopus, IPA) was conducted following PRISMA guidelines using the concepts 'neonates/children', 'vancomycin' and 'popPK model'. Inclusion criteria were age 0-18 years, intravenous vancomycin, and popPK model development. Descriptive statistics summarized tested vs. retained covariates. Based on literature and multidisciplinary expert input, model selection criteria were proposed and applied to the identified models. Across 7915 articles, 112 popPK models were identified (1994-2025; 35 neonatal, 6 infantile, 39 paediatric, 2 adolescent, 30 mixed-age). Models were built on data from median (range) 114 (6-7167) patients, representing 337 (26-13 372) PK samples. There were 81 one- and 30 two-compartment models. Of 180 covariates tested across models, 47 (26.1%) were retained. Body weight was most frequently tested and retained (101/106, 95.3%). Model selection criteria included matching population, external and internal model evaluation (calibration, discrimination, uncertainty), cohort size, PK sampling schedule. The Chen (2023) model scored highest for both the neonatal and paediatric populations. This review and model selection tool can guide and standardize model selection for MIPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.